糖尿病前期与全因死亡及心血管疾病风险的关联:更新版荟萃分析
该更新版荟萃分析纳入129项前瞻性队列研究或临床试验事后分析、共10 069 955人,评估糖尿病前期与全因死亡及心血管疾病风险的关联。一般人群中糖尿病前期与全因死亡、复合心血管疾病、冠心病和卒中风险均升高相关;在动脉粥样硬化性心血管疾病患者中,糖尿病前期与全因死亡、复合心血管疾病和冠心病风险升高相关,但卒中风险无显著差异。
要点
- 一般人群中糖尿病前期与全因死亡及心血管疾病风险升高相关。
- 动脉粥样硬化性心血管疾病患者中糖尿病前期与全因死亡和冠心病风险升高相关。
- 糖耐量受损较空腹血糖受损的全因死亡、冠心病和卒中风险更高。
核心结论
- 糖尿病前期与一般人群及动脉粥样硬化性心血管疾病患者的全因死亡和心血管疾病风险升高相关。
- 筛查和适当管理糖尿病前期可能有助于心血管疾病的一级和二级预防。
研究设计与样本
- 更新版荟萃分析,检索PubMed、Embase和Google Scholar至2020年4月25日。
- 纳入报告校正相对风险、比值比或风险比的前瞻性队列研究或临床试验事后分析。
- 共纳入129项研究,涉及10 069 955人进行分析。
- 采用随机效应模型计算相对风险和95%置信区间。
主要发现
- 一般人群中,糖尿病前期与全因死亡风险升高相关(相对风险1.13,95%置信区间1.10至1.17),中位随访9.8年。
- 一般人群中,糖尿病前期与复合心血管疾病(1.15,1.11至1.18)、冠心病(1.16,1.11至1.21)和卒中(1.14,1.08至1.20)风险升高相关。
- 动脉粥样硬化性心血管疾病患者中,糖尿病前期与全因死亡(1.36,1.21至1.54)、复合心血管疾病(1.37,1.23至1.53)和冠心病(1.15,1.02至1.29)风险升高相关,中位随访3.2年。
- 动脉粥样硬化性心血管疾病患者中,糖尿病前期与卒中风险无显著差异(1.05,0.81至1.36)。
- 糖耐量受损较空腹血糖受损的全因死亡、冠心病和卒中风险更高。
关键数值与推荐
- 一般人群中,糖尿病前期与正常血糖相比,全因死亡绝对风险差为每10 000人年7.36(95%置信区间9.59至12.51)。
- 一般人群中,糖尿病前期与正常血糖相比,复合心血管疾病绝对风险差为每10 000人年8.75(6.41至10.49)。
- 一般人群中,糖尿病前期与正常血糖相比,冠心病绝对风险差为每10 000人年6.59(4.53至8.65),卒中为3.68(2.10至5.26)。
- 动脉粥样硬化性心血管疾病患者中,糖尿病前期与正常血糖相比,全因死亡绝对风险差为每10 000人年66.19(38.60至99.25)。
- 动脉粥样硬化性心血管疾病患者中,糖尿病前期与正常血糖相比,复合心血管疾病绝对风险差为每10 000人年189.77(117.97至271.84)。
临床怎么用
- 在一般人群和动脉粥样硬化性心血管疾病患者中,应关注糖尿病前期的筛查。
- 对糖尿病前期进行适当管理可能有助于心血管疾病的一级和二级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the associations between prediabetes and the risk of all cause mortality and incident cardiovascular disease in the general population and in patients with a history of atherosclerotic cardiovascular disease. DESIGN: Updated meta-analysis. DATA SOURCES: Electronic databases (PubMed, Embase, and Google Scholar) up to 25 April 2020. REVIEW METHODS: Prospective cohort studies or post hoc analysis of clinical trials were included for analysis if they reported adjusted relative risks, odds ratios, or hazard ratios of all cause mortality or cardiovascular disease for prediabetes compared with normoglycaemia. Data were extracted independently by two investigators. Random effects models were used to calculate the relative risks and 95% confidence intervals. The primary outcomes were all cause mortality and composite cardiovascular disease. The secondary outcomes were the risk of coronary heart disease and stroke. RESULTS: A total of 129 studies were included, involving 10 069 955 individuals for analysis. In the general population, prediabetes was associated with an increased risk of all cause mortality (relative risk 1.13, 95% confidence interval 1.10 to 1.17), composite cardiovascular disease (1.15, 1.11 to 1.18), coronary heart disease (1.16, 1.11 to 1.21), and stroke (1.14, 1.08 to 1.20) in a median follow-up time of 9.8 years. Compared with normoglycaemia, the absolute risk difference in prediabetes for all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke was 7.36 (95% confidence interval 9.59 to 12.51), 8.75 (6.41 to 10.49), 6.59 (4.53 to 8.65), and 3.68 (2.10 to 5.26) per 10 000 person years, respectively. Impaired glucose tolerance carried a higher risk of all cause mortality, coronary heart disease, and stroke than impaired fasting glucose. In patients with atherosclerotic cardiovascular disease, prediabetes was associated with an increased risk of all cause mortality (relative risk 1.36, 95% confidence interval 1.21 to 1.54), composite cardiovascular disease (1.37, 1.23 to 1.53), and coronary heart disease (1.15, 1.02 to 1.29) in a median follow-up time of 3.2 years, but no difference was seen for the risk of stroke (1.05, 0.81 to 1.36). Compared with normoglycaemia, in patients with atherosclerotic cardiovascular disease, the absolute risk difference in prediabetes for all cause mortality, composite cardiovascular disease, coronary heart disease, and stroke was 66.19 (95% confidence interval 38.60 to 99.25), 189.77 (117.97 to 271.84), 40.62 (5.42 to 78.53), and 8.54 (32.43 to 61.45) per 10 000 person years, respectively. No significant heterogeneity was found for the risk of all outcomes seen for the different definitions of prediabetes in patients with atherosclerotic cardiovascular disease (all P>0.10). CONCLUSIONS: Results indicated that prediabetes was associated with an increased risk of all cause mortality and cardiovascular disease in the general population and in patients with atherosclerotic cardiovascular disease. Screening and appropriate management of prediabetes might contribute to primary and secondary prevention of cardiovascular disease.
引用
- Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020. PMID: 32669282. doi:10.1136/bmj.m2297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。